Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Efonidipine hydrochloride ethanolate
RN: 111011-76-8
UNII: 84HJ0Q6TMN
InChIKey: IKBJGZQVVVXCEQ-UHFFFAOYSA-N

Classification Codes

  • Drug / Therapeutic Agent
  • Reproductive Effect

Molecular Formulas

  • C34-H38-N3-O7-P.C2-H6-O.Cl-H
  • C34-H38-N3-O7-P.Cl-H.C2-H6-O

Molecular Weight

  • 714.192
 
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Results Name

  • Efonidipine hydrochloride ethanolate

Name of Substance

  • Efonidipine hydrochloride ethanol

Synonyms

  • Efonidipine HCl ethanolate
  • Efonidipine hydrochloride
  • Efonidipine hydrochloride ethanolate
  • Ethanol, compd. with 2-(phenyl(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P-oxide monohydrochloride (1:1)
  • Ethanol, compd. with 2-(phenyl(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate monohydrochloride
  • NZ 105 ethanolate
  • UNII-84HJ0Q6TMN

Systematic Names

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide, monohydrochloride
  • 3-Pyridinecarboxylic acid, 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, monohydrochloride, compd. with ethanol (1;1)

Registry Numbers

CAS Registry Number

  • 111011-76-8

FDA UNII

  • 84HJ0Q6TMN

System Generated Number

  • 0111011768

Molecular Formulas

Molecular Formulas

  • C34-H38-N3-O7-P.C2-H6-O.Cl-H
  • C34-H38-N3-O7-P.Cl-H.C2-H6-O

Molecular Formula Fragments

  • C2-H6-O
  • C34-H38-N3-O7-P
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C34H38N3O7P.C2H6O.ClH/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45;1-2-3;/h5-17,20,31,35H,18-19,21-23H2,1-4H3;3H,2H2,1H3;1H

InChIKey

IKBJGZQVVVXCEQ-UHFFFAOYSA-N

Smiles

Cl.P1(=O)(OCC(CO1)(C)C)C=1[C@@H](C(=C(NC1C)C)C(=O)OCCN(Cc1ccccc1)c1ccccc1)c1cc(ccc1)[N+](=O)[O-].C(C)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LDLo oral 3gm/kg (3000mg/kg) BLOOD: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: EMPHYSEMA

KIDNEY, URETER, AND BLADDER: OTHER CHANGES
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
mouse LD50 intraperitoneal 365mg/kg (365mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
mouse LD50 intravenous 77mg/kg (77mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

SKIN AND APPENDAGES (SKIN): HAIR: OTHER

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
mouse LD50 oral 1805mg/kg (1805mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
mouse LD50 subcutaneous > 5gm/kg (5000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
rat LD50 intraperitoneal 161mg/kg (161mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
rat LD50 intravenous 43mg/kg (43mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
rat LD50 intravenous 43mg/kg (43mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
rat LD50 oral > 5gm/kg (5000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,
rat LD50 subcutaneous > 5gm/kg (5000mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl,